Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Geron Corp (GERN)
NASDAQ:GERN
Holding GERN?
Track your performance easily
GERN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.64 - $5.34
Previous CloseN/A
Volume1.63M
Average Volume (3M)12.36M
Market Cap
$1.82B
Enterprise Value$2.75B
Total Cash (Recent Filing)$114.84M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Mar 06, 2025EPS Estimate
-0.03Last Dividend Ex-Date
Jul 22, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.32
Shares Outstanding604,501,040
10 Day Avg. Volume9,786,193
30 Day Avg. Volume12,358,937
Standard Deviation0.18
R-Squared0.03
Alpha0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)61.72
Price to Cash Flow (P/CF)-7.70
P/FCF Ratio0.00
Enterprise Value/Market Cap1.51
Enterprise Value/Revenue93.35
Enterprise Value/Gross Profit11.61K
Enterprise Value/Ebitda-14.92
Forecast
1Y Price Target
$8.20Price Target Upside183.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Geron News
PremiumCompany Announcements
Geron to Showcase RYTELO Success at Healthcare Conference
PremiumCompany Announcements
Geron Corporation’s Q3 2024: Strong RYTELO Launch and Financial Growth
Bulls Say, Bears Say
Bulls Say
EarningsThe company's revenue for the quarter was pre-reported at $45-46 million, representing approximately 60% growth over the previous quarter, showcasing strong numbers in the early launch phase.
Financial PerformanceGeron ended the year with approximately $500 million in cash, demonstrating strong financial health and stability.
Product DevelopmentThe EU Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Rytelo in patients with LR-MDS, helping to de-risk potential EU approval and indicating a significant step forward for the product's market expansion.
Bears Say
Earnings ExpectationsThe 4Q24 pre-announce is approximately in line with consensus and our estimate, but may come in slightly below more optimistic buy-side expectations.
Investor ConcernsInvestors were confused on how the company rephrased their cash runway guidance.
Product Launch StrategyDue to the high costs associated with launching a new product ex-US, Geron is carefully selecting which countries it plans to commercialize Rytelo.
---
Ownership Overview
0.16% Insiders
13.10% Mutual Funds
0.12% Other Institutional Investors
72.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GERN FAQ
What was Geron Corp’s price range in the past 12 months?
Geron Corp lowest stock price was $1.64 and its highest was $5.34 in the past 12 months.
What is Geron Corp’s market cap?
Geron Corp’s market cap is $1.82B.
When is Geron Corp’s upcoming earnings report date?
Geron Corp’s upcoming earnings report date is Mar 06, 2025 which is in 34 days.
How were Geron Corp’s earnings last quarter?
Geron Corp released its earnings results on Nov 07, 2024. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.084 by $0.044.
Is Geron Corp overvalued?
According to Wall Street analysts Geron Corp’s price is currently Undervalued.
Does Geron Corp pay dividends?
Geron Corp pays a Notavailable dividend of $0.149 which represents an annual dividend yield of N/A. See more information on Geron Corp dividends here
What is Geron Corp’s EPS estimate?
Geron Corp’s EPS estimate is -0.03.
How many shares outstanding does Geron Corp have?
Geron Corp has 604,501,040 shares outstanding.
What happened to Geron Corp’s price movement after its last earnings report?
Geron Corp reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.084. Following the earnings report the stock price went up 0.468%.
Which hedge fund is a major shareholder of Geron Corp?
Currently, no hedge funds are holding shares in GERN
---
Geron Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.20 (183.74% Upside)
$8.20 (183.74% Upside)
Blogger Sentiment
Bullish
GERN Sentiment 88%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 37.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.1%
Last 30 Days ▲ 5.5%
Last 30 Days ▲ 5.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.71%
12-Months-Change
Fundamentals
Return on Equity
-69.03%
Trailing 12-Months
Asset Growth
7.73%
Trailing 12-Months
Company Description
Geron Corp
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Menlo Park, CA.
---
GERN Company Deck
---
GERN Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong start for RYTELO's market presence, successful financial strategies, and promising growth potential both in the U.S. and internationally. However, high operating expenses and the dependency on market success pose challenges.Read More>---
GERN Stock 12 Month Forecast
Average Price Target
$8.20
▲(183.74% Upside)
Technical Analysis
Cyclacel Pharmaceuticals
―
Exelixis
―
Karyopharm Therapeutics
―
Sorrento Therapeutics
―
Best Analysts Covering GERN
1 Year
1 Year Success Rate
14/21 ratings generated profit
1 Year Average Return
+36.85%
reiterated a buy rating 6 months ago
Copying Kalpit Patel's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +36.85% per trade.
---